PLRZ (polyrizon-biotech.com) Multiplikator Forward P/S

Polyrizon Ltd generates revenue by creating nasal sprays that block allergens and viruses. Business scalability is driven by royalties from partners without the need for capital expenditure on manufacturing plants. Reliable international routes ensure the uninterrupted delivery of bioccomponents. The forward P/S trend reflects a market revaluation of assets, with the value stabilizing at 0.00, providing a real-time assessment of current demand for the securities.

The robotization of bio-barrier synthesis and the automation of packaging at Polyrizon Ltd (PLRZ) directly drive revenue dynamics, as reflected in the forward P/S valuation history. The current value of 0.00 demonstrates the ratio of market capitalization to expected sales, allowing investors to assess the premium paid for future commercial success and verify market demand for the issuer's high-tech solutions.